March 18, 2024: New drug for common liver disease; 4 cancer drugs, OTC continuous glucose monitor, Prolia generic, Puberty blockers blocked; 2023 generics report; how drug samples may affect care
March 18, 2024: New drug for common liver disease; 4 cancer drugs, OTC continuous glucose monitor, Prolia generic, Puberty blockers blocked; 2023 generics report; how drug samples may affect care
news.askapatient.com
New Drug Approvals The U.S. Food and Drug Administration (FDA) approved Madrigal Pharmaceutical's Rezdiffra (resmetirom) for patients noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis). NASH, a common liver disease, is a result of the progression of
March 18, 2024: New drug for common liver disease; 4 cancer drugs, OTC continuous glucose monitor, Prolia generic, Puberty blockers blocked; 2023 generics report; how drug samples may affect care
March 18, 2024: New drug for common liver…
March 18, 2024: New drug for common liver disease; 4 cancer drugs, OTC continuous glucose monitor, Prolia generic, Puberty blockers blocked; 2023 generics report; how drug samples may affect care
New Drug Approvals The U.S. Food and Drug Administration (FDA) approved Madrigal Pharmaceutical's Rezdiffra (resmetirom) for patients noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis). NASH, a common liver disease, is a result of the progression of